Impact of NPM1 mutation subtypes on treatment outcome in AML: The Lyon-University Hospital experience

Leuk Res. 2019 Jan:76:29-32. doi: 10.1016/j.leukres.2018.11.016. Epub 2018 Nov 29.

Authors

Maël Heiblig¹, Pierre Sujobert², Sandrine Hayette², Marie Balsat¹, Mohamed Elhamri¹, Gilles Salles¹, Xavier Thomas³

Affiliations

¹ Hospices Civils de Lyon, Department of Hematology, Lyon-Sud Hospital, Pierre-Bénite, France.
² Hospices Civils de Lyon, Laboratory of Molecular Biology, Lyon-Sud Hospital, Pierre-Bénite, France.
³ Hospices Civils de Lyon, Department of Hematology, Lyon-Sud Hospital, Pierre-Bénite, France. Electronic address: xavier.thomas@chu-lyon.fr.

PMID: 30529680
DOI: 10.1016/j.leukres.2018.11.016

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Biomarkers, Tumor
Humans
Leukemia, Myeloid, Acute / genetics*
Leukemia, Myeloid, Acute / mortality*
Leukemia, Myeloid, Acute / therapy
Mutation*
Nuclear Proteins / genetics*
Nucleophosmin
Prognosis
Treatment Outcome

Substances

Biomarkers, Tumor
NPM1 protein, human
Nuclear Proteins
Nucleophosmin